Pradaxa Shines On Strength Of Results, But Panelists Wary Of Future Trials With Similar Design
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehinger Ingelheim's dabigatran eked out a unanimous endorsement from FDA's Cardio-Renal Advisory Committee, but the panel had concerns about the potential for bias from the open-label trial design.